期刊文献+

抗肿瘤药物治疗中临床药师的干预技巧 被引量:8

Intervention Skills of Clinical Pharmacists in Anticancer Drug Treatment
下载PDF
导出
摘要 目的探讨肿瘤科临床药师干预临床合理用药的工作思路和技巧。方法临床药师可通过对化疗药及辅助用药的选择、剂量的调整、药物的相互作用及用药教育等几方面协助医师用药。结果与结论临床药师通过有效途径干预肿瘤患者的临床用药,提升了合理用药水平,减少了不良反应的发生率,从而提高了患者的生存质量。 Objective To discuss the working ideas and skills of clinical pharmacists in Department of Oncology on intervention of clinical rational drug use. Methods The clinical pharmacist could assist physicians in medication from aspects of the choice of chemotherapy drugs and adjuvant drugs, dose adjustment, drug interactions, drug education and so on. Results and Conclusion Clinical pharmacists'intervention in clinical medication of tumor patients by effective ways improved rational drug use, reduced the incidence of adverse reactions, thus improving patients'life quality.
出处 《中国药事》 CAS 2013年第1期97-99,共3页 Chinese Pharmaceutical Affairs
关键词 肿瘤科 药师 干预 合理用药 department of oneology pharmacist intervention rational drug use
  • 相关文献

参考文献9

  • 1张蕾,赵荣生,翟所迪.神经科专科药师的特点与培养路径探讨[J].中国药房,2008,19(8):630-632. 被引量:2
  • 2中国弥漫大B细胞淋巴瘤诊断与治疗指南[J].中华血液学杂志,2011,32(10):724-726. 被引量:40
  • 3Launchbury AP, Habboubi N. Epruibicin and doxorubicin.. A comparison of their characteristics, therapeutic activity and toxic ity [J]. Cancer Treat Rev, 1993, 19 (3): 197-228.
  • 4Oermanakis I, Anagnostatou N, Kalmanti M. Troponins and natriuretic peptides in the monitoring of anthracycline cardiotoxici ty [J]. Pediatr Blood Cancer, 2008, 51 (3) : 327-333.
  • 5Pouillart P. Evaluating the role of dexrazoxane as a cardio protectant in cancer patients receiving anthracyclines [J]. Cancer Treat Rev, 2004, 30 (7): 643-650.
  • 6王渊,韩冬.盐酸帕洛诺司琼注射液在化疗抗吐方面的作用及应用前景[J].医药论坛杂志,2010,31(15):202-204. 被引量:3
  • 7FDA Drug Safety Communication. Abnormal heart rhythms as- sociated with llse of Anzemet (dolasetron mesylate) [EB/OL] . (2011 04 02) [-2011-04-16 ]http: //www. fda. gov/Drugs/ DrugSafety/uern237081. htm.
  • 8Longfield V. Compatibility and stability of 5 HT3 receptor antagonists.- a pharmacology review [J]. Oncol Nurs Fo- rum, 2002, 29 (20): 1469-1482.
  • 9Paz-Ares LG, Smith MR. Genitourinary malignancies [J]. Cancer Chemother Biol Response Modi, 2001, (19) : 573- 595.

二级参考文献22

  • 1胡凯,丁鼎乐.帕洛诺司琼市场前景看好[J].上海医药,2004,25(11):518-518. 被引量:8
  • 2张乃文,齐晓涟,王育琴.做好药师与患者的沟通是癫用药教育的关键[J].药学服务与研究,2005,5(4):362-365. 被引量:3
  • 3Wong EH, Clark R, Leung E, et al. The interaction of RS 25259 -197, a potent and selective antagonist, with 5 - HT3 receptors, in vitro [ J ]. Br J Pharmacol, 1995 Feb, 114(4) :851-9.
  • 4Eglen RM, Lee CH, Smith WL, et al. Pharmacological characterization of RS 25259 - 197, a novel and selec- tive 5 - HT3 receptor antagonist, in vivo [ J ]. Br J Pharmacol, 1995, 114(4) :860-6.
  • 5Grunberg SM, Koeller JM.Palonosetron : a unique 5 - HT3 - receptor antagonist for the prevention of chemotherapy - induced emesis [ J ]. Expert Opin Pharmacother, 2003 Dec,4(12) :2297-303.
  • 6Eisenberg P, MacKintosh FR, Ritch P, et al.Efficacy, safety and pharmacokinetics of palonosetron in patients receiving highly emetogenic cisplatin -based chemotherapy: a dose - ranging clinical study [ J]. Ann Oncol, 2004 Feb, 15(2) : 330-7.
  • 7Hunt TL, Gallagher SC, Cullen MT JR, et al. Evaluation of safety and pharmacokinetics of consecutive multiple -day dosing of palonosetron in healthy subjects[ J]. J Cliu Phannacol, 2005, 45(5 ) :589-96.
  • 8Stoltz R, Parisi S, Shah A, et al. Pharmacokinetics, metabolism and excretion of intravenous [ 14C ] - palonosetron in healthy human volunteers [ J ]. Biopharm Drug Dispos, 200,25(8) :329-37.
  • 9Gralla R, Lichinitser M, Van Der Vegt S, et al. Palonosetron improves prevention of chemotherapy - in- duced nausea and vomiting following moderately emetogenic chemotherapy : results of a double - blind randomized phase III trial comparing: single doses of palonosetron with ondansetron [ J ]. Ann Oncol, 2003 Oct, 14 (10) : 1570-7.
  • 10Eisenberg P, Figueroa -Vadillo J, Zamora R, et al. Improved prevention of moderately ernetogenic chemo- therapy - induced nausea and vomiting with palonosetron, a pharmacologically novel 5 - HT3 receptor antagonist: results of a phase III, single - dose trial versus dolasetron[ J]. Cancer, 2003, 98 ( 11 ) 2473-82.

共引文献42

同被引文献44

引证文献8

二级引证文献27

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部